Navidea Biopharmaceuticals Overview
- Year Founded
-
1983
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
NAVB
Navidea Biopharmaceuticals General Information
Description
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Contact Information
Website
www.navidea.comCorporate Office
- 4995 Bradenton Avenue
- Suite 240
- Dublin, OH 43017
- United States
Corporate Office
- 4995 Bradenton Avenue
- Suite 240
- Dublin, OH 43017
- United States
Navidea Biopharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $100K | 100M | 12.6K | -$0.08 |
Navidea Biopharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 4,465 | 4,308 | 24,124 | 55,418 |
| Revenue | 1 | 15 | 46 | 119 |
| EBITDA | (8,502) | (13,983) | (11,632) | (10,663) |
| Net Income | (1,182) | (15,177) | (11,731) | (10,722) |
| Total Assets | 5,699 | 4,372 | 6,645 | 7,758 |
| Total Debt | 1,260 | 2,436 | 749 | 1,336 |
Navidea Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Navidea Biopharmaceuticals Comparisons
Industry
Financing
Details
0000 0
000000
Navidea Biopharmaceuticals Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
| Lineage Cell Therapeutics | Corporation | Carlsbad, CA | 00 | 00000 | 000000000 | 00000 |
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
| Precirix | Venture Capital-Backed | Brussels, Belgium | 00 | 00000 | 00000000000 | 00000 |
| Alaunos Therapeutics | Formerly VC-backed | Houston, TX | 00 | 00000 | 00000000000 | 00000 |
Navidea Biopharmaceuticals Patents
Navidea Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240132630-A1 | Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers | Pending | 03-Oct-2022 | 00000000000 | 0 |
| US-20240024491-A1 | Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells | Pending | 13-Jul-2022 | 000000000 | |
| US-20230374055-A1 | Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker | Active | 20-May-2022 | 000000000 | |
| US-12006339-B2 | Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker | Active | 20-May-2022 | 000000000 | 00 |
| US-20240294564-A1 | Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker | Pending | 20-May-2022 | C07H13/12 |
Navidea Biopharmaceuticals Executive Team (18)
| Name | Title | Board Seat |
|---|---|---|
| Michael Rosol | Chief Executive Officer & Chief Medical Officer | |
| Craig A. Dais | Chief Financial Officer | |
| Michel Mikhail Ph.D | Chief Regulatory Officer | |
| Michael Blue MD | Chief Medical Officer |
Navidea Biopharmaceuticals Board Members (20)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 00000 00. | Self | Board Member & Vice Chairman | 000 0000 |
Navidea Biopharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Navidea Biopharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Navidea Biopharmaceuticals Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Cardinal Milestone Payment | Other Financial Services |
Navidea Biopharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Navidea Biopharmaceuticals FAQs
-
When was Navidea Biopharmaceuticals founded?
Navidea Biopharmaceuticals was founded in 1983.
-
Who is the CEO of Navidea Biopharmaceuticals?
Michael Rosol is the CEO of Navidea Biopharmaceuticals.
-
Where is Navidea Biopharmaceuticals headquartered?
Navidea Biopharmaceuticals is headquartered in Dublin, OH.
-
What is the size of Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals has 15 total employees.
-
What industry is Navidea Biopharmaceuticals in?
Navidea Biopharmaceuticals’s primary industry is Biotechnology.
-
Is Navidea Biopharmaceuticals a private or public company?
Navidea Biopharmaceuticals is a Public company.
-
What is Navidea Biopharmaceuticals’s stock symbol?
The ticker symbol for Navidea Biopharmaceuticals is NAVB.
-
What is the current market cap of Navidea Biopharmaceuticals?
The current market capitalization of Navidea Biopharmaceuticals is $100K.
-
What is Navidea Biopharmaceuticals’s current revenue?
The trailing twelve month revenue for Navidea Biopharmaceuticals is $610.00.
-
Who are Navidea Biopharmaceuticals’s competitors?
Fate Therapeutics, Lineage Cell Therapeutics, Regulus Therapeutics, Precirix, and Alaunos Therapeutics are some of the 12 competitors of Navidea Biopharmaceuticals.
-
What is Navidea Biopharmaceuticals’s annual earnings per share (EPS)?
Navidea Biopharmaceuticals’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
